<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614146</url>
  </required_header>
  <id_info>
    <org_study_id>1438</org_study_id>
    <secondary_id>ISRCTN67377557</secondary_id>
    <nct_id>NCT00614146</nct_id>
  </id_info>
  <brief_title>Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>Therapeutic Impact of Albumin Dialysis With the Molecular Adsorbents Recirculating System (MARS®) in Severely Decompensated Chronic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>2ConduCT</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>G.E.M. mbh Meerbusch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DatInf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gambro Lundia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate the impact of elimination of albumin bound
      substances during albumin dialysis (MARS®) on mortality and the clinical time course in
      patients with a recent severe clinical deterioration of chronic liver disease caused by a
      precipitating (trigger) event within 4 weeks manifested by jaundice, encephalopathy and/or
      renal failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current medical therapy for end stage liver disease is focused on substitution of blood or
      plasma products, volume expansion or antibiotic treatment. The only specific treatment is
      liver transplantation, which is limited by available organs and may be a therapeutic option
      only for a very minority of patients with recently deteriorated end stage liver disease. The
      clinical management of defect hepatic synthesis and metabolic regulation has been improved
      dramatically within the past decades by the development of transfusion and intensive care
      medicine, but the replacement of detoxification has been more difficult, as the majority of
      endogenous toxins accumulating in liver failure is bound to albumin. Therefore, conventional
      dialysis and hemofiltration have been shown to be ineffective for their removal. The present
      study is based on the theory, that supporting the failing liver by the removal of toxic
      substances with a biocompatible method (the MARS system) may improve the capacity for
      recovery of the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Show improvement of transplant free survival under MARS in comparison to Standard Medical Treatment.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival regardless of transplantation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>general survival</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-hospital mortality</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time course of clinical state (number and severity of complications, vital signs, scoring systems, lab tests)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>economic analysis (length of stay, ICU days, readmissions within observation period)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MARS device</intervention_name>
    <description>10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Liver support</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard medical therapy</intervention_name>
    <description>Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol</description>
    <arm_group_label>2</arm_group_label>
    <other_name>SMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard medical therapy</intervention_name>
    <description>Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent by patient or next of kin

          -  Age greater than 18 years

          -  Patients with a recent clinical severe decompensation of a presumed cirrhosis (based
             on clinical evaluation or radiological imaging) related to a precipitating (trigger)
             event (e.g. infection, bleeding, alcohol abuse)

          -  Intrahepatic cholestasis (bilirubin greater than 5 mg/dl or greater than 85 µmol/l,
             respectively) without evidence of extrahepatic origin

          -  and at least one of the following three:

          -  Hepatorenal syndrome (impaired renal function with creatinine greater than 1.5 mg/dl
             or greater than 133µmol/l without evidence of reduced vascular volume [e.g. central
             venous pressure {CVP} greater than 8 cm H2O] and no evidence of pre-existing renal
             failure)

          -  Hepatic Encephalopathy greater than or equal to II°

          -  Progressive Hyperbilirubinaemia: defined as a more than 50% increase of bilirubin
             before enrolment, whether in referral or currently in hospital up to a level of
             greater than 20 mg/dl (or greater than 340 µmol/l)

        Exclusion Criteria:

          -  Progressive jaundice and deterioration as a natural course of a chronic liver disease
             without precipitating (trigger) event

          -  Severe thrombocytopenia (platelet count less than or equal to 50 Glutamic Pyruvic
             Transaminase [GPT]/l)

          -  Severe coagulopathy (International Normalised Ratio [INR] greater than 2.3)

          -  Need for renal replacement therapy within three days prior to enrolment

          -  Severe infection without antibiotic treatment for at least 24 hours. Uncontrolled
             bacterial infection

          -  Active bleeding within 48 hours prior to enrolment

          -  Proven hepatocellular carcinoma (HCC) greater than 4 cm or infiltration of portal vein
             or acute portal vein thrombosis

          -  Severe cardiopulmonary disease (New York Heart Association [NYHA] greater than or
             equal to 2)

          -  Pregnancy/lactation

          -  Mean arterial pressure (MAP) less than 60 mmHg despite vasopressor agents
             (norepinephrine greater than 1 µg/kg/min) for blood pressure support

          -  Overt clinical evidence for Disseminated Intravascular Coagulation (DIC)

          -  Clinical evidence for coma of non-hepatic origin

          -  Extra-hepatic cholestasis

          -  Severe intrinsic renal disease

          -  Extended surgical procedure within the last four weeks or unsolved surgical problems

          -  Known human immunodeficiency virus (HIV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Banarès, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Gregorio Maranon, Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Arroyo, Pf</last_name>
    <role>Study Chair</role>
    <affiliation>Clínic Barcelona, Hospital Universitari Villarroel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Williams, Pf</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Free and University College Medical School, University College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Mitzner, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Internal Medicine, University of Rostock</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuitzen</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Berlin, Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Luther Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätshospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE 5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>WC1E 6HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J. 1993 Jul-Sep;39(3):M621-5.</citation>
    <PMID>8268613</PMID>
  </reference>
  <reference>
    <citation>Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs. 1993 Sep;17(9):809-13.</citation>
    <PMID>8240075</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver failure, albumin dialysis, liver support</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

